Analysts expect Caladrius Biosciences Inc (NASDAQ:CLBS) to report ($0.83) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Caladrius Biosciences’ earnings. Caladrius Biosciences reported earnings per share of ($0.73) in the same quarter last year, which indicates a negative year over year growth rate of 13.7%. The company is scheduled to announce its next quarterly earnings results after the market closes on Friday, March 16th.
On average, analysts expect that Caladrius Biosciences will report full-year earnings of $2.02 per share for the current fiscal year. For the next fiscal year, analysts expect that the business will report earnings of ($3.36) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Caladrius Biosciences.
A number of equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Caladrius Biosciences in a report on Wednesday, March 14th. Zacks Investment Research lowered Caladrius Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th.
An institutional investor recently raised its position in Caladrius Biosciences stock. Macquarie Group Ltd. increased its stake in Caladrius Biosciences Inc (NASDAQ:CLBS) by 321.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 29,890 shares of the biotechnology company’s stock after buying an additional 22,790 shares during the quarter. Macquarie Group Ltd. owned about 0.32% of Caladrius Biosciences worth $105,000 as of its most recent filing with the SEC. Institutional investors own 5.75% of the company’s stock.
Caladrius Biosciences stock traded down $0.08 during trading on Monday, hitting $5.84. The stock had a trading volume of 14,834 shares, compared to its average volume of 90,036. The stock has a market cap of $56.07, a P/E ratio of 2.77 and a beta of 1.46. Caladrius Biosciences has a 52 week low of $2.63 and a 52 week high of $6.35.
ILLEGAL ACTIVITY WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/04/11/analysts-expect-caladrius-biosciences-inc-clbs-will-post-earnings-of-0-83-per-share.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.